Showing results (41-50 of 81) with videos related to
Sort By:
Pageof 9
IJU Case Reports|January 3, 2025
Afebrile tuberculous prostatic abscess with rectal fistula after intravesical Bacillus Calmette-Guérin immunotherapyTatsuhiro Sawada, Ayaka Igarashi, Seiji Arai, et al.Cancer Chemotherapy and Pharmacology|December 25, 2014
A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancerKazuhiro Suzuki, Seiichiro Ozono, Akito Yamaguchi, et al.Journal of Investigative Surgery : the Official Journal of the Academy of Surgical Research|October 14, 2016
Efficacy of Indocyanine Green Angiography on Microsurgical Subinguinal VaricocelectomyYasuhiro Shibata, Sota Kurihara, Seiji Arai, et al.Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|April 25, 2018
Assessment of antimicrobiral prophylaxis in transperineal prostate biopsy: A single-center retrospective study of 485 casesKyoko Baba, Yoshitaka Sekine, Yoshiyuki Miyazawa, et al.IJU Case Reports|November 4, 2025
Intermittent Recurrence of Ureterosciatic Hernia After Spontaneous Resolution, Complicated by Emphysematous PyelonephritisAkira Ohtsu, Keisuke Hori, Seiji Arai, et al.Anticancer Research|February 26, 2004
Association of the genetic polymorphism of the CYP19 intron 4[TTTA]n repeat with familial prostate cancer risk in a Japanese populationKazuhiro Suzuki, Haruki Nakazato, Hiroshi Matsui, et al.International Journal of Urology : Official Journal of the Japanese Urological Association|May 31, 2023
The utility of the [-2]pro-prostate-specific antigen level as a prognostic marker in patients with castration-resistant prostate cancer treated with enzalutamideYoshiyuki Miyazawa, Keisuke Hori, Yusuke Tsuji, et al.Basic and Clinical Andrology|July 7, 2015
Clinical endocrinological evaluation of the gonadal axis (testosterone, LH and FSH) in prostate cancer patients switched from a GnRH antagonist to a LHRH agonistYoshiyuki Miyazawa, Haruo Kato, Seiji Arai, et al.Oncology Letters|February 14, 2018
Simvastatin in combination with meclofenamic acid inhibits the proliferation and migration of human prostate cancer PC-3 cells via an AKR1C3 mechanismYoshitaka Sekine, Hiroshi Nakayama, Yoshiyuki Miyazawa, et al.International Journal of Cancer|April 27, 2018
Long-term longitudinal changes in baseline PSA distribution and estimated prevalence of prostate cancer in male Japanese participants of population-based PSA screeningRyo Oki, Kazuto Ito, Rie Suzuki, et al.Pageof 9